Nasdaq · Biotech stocks database
CELC — Celcuity Inc.
CELC (Celcuity Inc.) stock: $69.13, $3.38B market cap, $754.0M cash, $3.38B EV, $5.11B fully diluted market cap. Lead program: Gedatolisib (Breast Cancer), Phase 3. Data from Fully Diluted's biotech stocks database.
Enterprise value
$3,381.9M
Balance sheet
| Cash | $754.0M |
|---|
| Debt | $753.2M |
|---|
| Net cash | $0.8M |
|---|
| Enterprise value | $3,381.9M |
|---|
| Basic shares | 48.9M shares |
|---|
| Fully diluted shares | 73.9M shares |
|---|
| Fully diluted market cap | $5,106.6M |
|---|
| Cash per share | $15.41 |
|---|
| Quarterly burn | $55.4M |
|---|
| Cash runway | 13.6 quarters |
|---|
Cash figures as of 2026-06-30. Database snapshot: 2026-10-30.
Share structure
Cap table as of 2026-06-30.
Price history
Loading CELC daily closes…
Loading price history…
Asset data not yet available for this company.
Pipeline
| Lead drug | Gedatolisib |
|---|
| Lead indication | Breast Cancer |
|---|
| Lead phase | Phase 3 |
|---|
| Active trials | 5 |
|---|
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.